Evidence map›Paper›PMID 39363619›Full record

ArticleMacromolecular bioscience2024

Topical Application of Dexamethasone-Loaded Core-Multishell Nanocarriers Against Oral Mucosal Inflammation.

Cynthia V Yapto, Keerthana Rajes, Antonia Inselmann, Sven Staufenbiel, Kim N Stolte, Maren Witt, Rainer Haag, Henrik Dommisch, Kerstin Danker

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Macromolecular bioscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cynthia V YaptoInstitute of Biochemistry, Charité - Universitätsmedizin Berlin, 10117, Berlin, Germany.
Keerthana RajesFreie Universität Berlin, Institute of Chemistry and Biochemistry, 14195, Berlin, Germany.
Antonia InselmannInstitute of Biochemistry, Charité - Universitätsmedizin Berlin, 10117, Berlin, Germany.
Sven StaufenbielFreie Universität Berlin, Institute of Pharmacy, Pharmaceutical Technology, 12169, Berlin, Germany.
Kim N StolteCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Berlin, Germany.
Maren WittCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Berlin, Germany.
Rainer HaagFreie Universität Berlin, Institute of Chemistry and Biochemistry, 14195, Berlin, Germany.
Henrik DommischCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Berlin, Germany.
Kerstin DankerInstitute of Biochemistry, Charité - Universitätsmedizin Berlin, 10117, Berlin, Germany.

Funding

Berlin Institute of HealthDeutsche Forschungsgemeinschaft DA310/8-1Deutsche Forschungsgemeinschaft DO1375/2-1Deutsche Forschungsgemeinschaft HA2549/22-1Sonnenfeld Foundation
6 · The paper itself

Abstract

Topical treatment of oral inflammatory diseases is challenging due to the intrinsic physicochemical barriers of the mucosa and the continuous flow of saliva, which dilute drugs and limit their bioavailability. Nanocarrier technology can be an innovative approach to circumvent these problems and thus improve the efficacy of topical drug delivery to the mucosa. Core-multishell (CMS) nanocarriers are putative delivery systems with high biocompatibility and the ability to adhere to and penetrate the oral mucosa. Ester-based CMS nanocarriers release the anti-inflammatory compound dexamethasone (Dx) more efficiently than a conventional cream. Mussel-inspired functionalization of a CMS nanocarrier with catechol further improves the adhesion of the nanocarrier and may enhance the efficacy of the loaded drugs. In the present study, the properties of the ester-based CMS 10-E-15-350 nanocarrier (CMS-NC) are further evaluated in comparison to the catechol-functionalized variant (CMS-C

Indexed as

Anti-Inflammatory AgentsDexamethasoneDrug CarriersMouth MucosaAdministration, TopicalAnimalsHumansInflammationNanoparticlesSalivaAnti-Inflammatory AgentsDexamethasoneDrug Carrierscore‐multishell nanocarrierdexamethasonedrug deliveryepithelial cellsoral mucosal inflammation

Identifiers

PMID39363619
PMCPMC11648588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.